Department of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Department of Neurosurgery, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Cells. 2024 Apr 12;13(8):671. doi: 10.3390/cells13080671.
Ischemic stroke is a major cerebrovascular disease with high morbidity and mortality rates; however, effective treatments for ischemic stroke-related neurological dysfunction have yet to be developed. In this study, we generated neural progenitor cells from human leukocyte antigen major loci gene-homozygous-induced pluripotent stem cells (hiPSC-NPCs) and evaluated their therapeutic effects against ischemic stroke. hiPSC-NPCs were intracerebrally transplanted into rat ischemic brains produced by transient middle cerebral artery occlusion at either the subacute or acute stage, and their in vivo survival, differentiation, and efficacy for functional improvement in neurological dysfunction were evaluated. hiPSC-NPCs were histologically identified in host brain tissues and showed neuronal differentiation into vGLUT-positive glutamatergic neurons, extended neurites into both the ipsilateral infarct and contralateral healthy hemispheres, and synaptic structures formed 12 weeks after both acute and subacute stage transplantation. They also improved neurological function when transplanted at the subacute stage with γ-secretase inhibitor pretreatment. However, their effects were modest and not significant and showed a possible risk of cells remaining in their undifferentiated and immature status in acute-stage transplantation. These results suggest that hiPSC-NPCs show cell replacement effects in ischemic stroke-damaged neural tissues, but their efficacy is insufficient for neurological functional improvement after acute or subacute transplantation. Further optimization of cell preparation methods and the timing of transplantation is required to balance the efficacy and safety of hiPSC-NPC transplantation.
缺血性脑卒中是一种具有高发病率和死亡率的主要脑血管疾病;然而,针对缺血性脑卒中相关神经功能障碍的有效治疗方法尚未得到开发。在本研究中,我们从人类白细胞抗原主要组织相容性基因纯合诱导多能干细胞(hiPSC-NPC)中产生神经祖细胞,并评估其对缺血性脑卒中的治疗效果。将 hiPSC-NPC 分别在亚急性期和急性期通过短暂性大脑中动脉闭塞移植到大鼠缺血性脑内,并评估其在体内的存活、分化以及改善神经功能障碍的效果。在宿主脑组织中对 hiPSC-NPC 进行组织学鉴定,发现其分化为 vGLUT 阳性谷氨酸能神经元,向同侧梗死和对侧健康半球延伸神经突,并在急性和亚急性期移植后 12 周形成突触结构。在亚急性期进行移植并预先用 γ-分泌酶抑制剂处理可改善神经功能。然而,其效果并不显著,并且在急性移植时可能存在细胞保持未分化和不成熟状态的风险。这些结果表明,hiPSC-NPC 在缺血性脑卒中损伤的神经组织中显示出细胞替代作用,但在急性或亚急性期移植后改善神经功能的效果不足。需要进一步优化细胞制备方法和移植时机,以平衡 hiPSC-NPC 移植的疗效和安全性。